Wedbush Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $9 to $7.
Wedbush analyst David Nierengarten maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $9 to $7.